Evidence map›Paper›PMID 31244284›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2019

Differential Profile of BRCA1 vs. BRCA2 Mutated Families: A Characterization of the Main Differences and Similarities in Patients.

Gabriela Carvalho Fernandes, Paula Silva Felicio, Rodrigo Augusto Depieri Michelli, Aline Silva Coelho, Cristovam Scapulatempo-Neto, Edenir Inêz Palmero

Open access · goldAbstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Histological and Immunohistochemical Characteristics for Hereditary Breast Cancer Risk in a Cohort of Brazilian Women.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2022
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Gabriela Carvalho FernandesMolecular Oncology Research Center, Barretos Cancer Hospital, Brazil. Email: edenirip@yahoo.com.br
Paula Silva FelicioMolecular Oncology Research Center, Barretos Cancer Hospital, Brazil. Email: edenirip@yahoo.com.br
Rodrigo Augusto Depieri MichelliDepartment of Oncogenetics, Barretos Cancer Hospital, Brazil.
Aline Silva CoelhoMolecular Oncology Research Center, Barretos Cancer Hospital, Brazil. Email: edenirip@yahoo.com.br
Cristovam Scapulatempo-NetoMolecular Oncology Research Center, Barretos Cancer Hospital, Brazil. Email: edenirip@yahoo.com.br
Edenir Inêz PalmeroMolecular Oncology Research Center, Barretos Cancer Hospital, Brazil. Email: edenirip@yahoo.com.brORCID 0000-0003-1904-2158
Hospital de Câncer de Barretos · BRInstituto Barretos de Tecnologia · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The identification of families at-risk for hereditary breast cancer (BC) is important because affected individuals present a much higher cancer risk than the general population. The aim of this study was to identify the most important factors associated with the presence of a pathogenic BRCA1/BRCA2 mutation. Family history (FH), histopathological and immunohistochemical characteristics were compared among BC women with pathogenic BRCA1/BRCA2 variants; VUSs in BRCA1/BRCA2; BRCA1/BRCA2 WT and sporadic BC. The most significative differences observed concerned the molecular subtype of the tumors, age at cancer diagnosis and FH of cancer. The presence of bilateral breast cancer (BBC), number of BC cases and the presence of ovarian cancer (OC) increased (respectively) 5.797, 5.033 and 4.412 times the risk of being a BRCA1/BRCA2 mutation carrier. Besides, women with BRCA1 or BRCA2 mutations presented different tumor and FH profiles. The main characteristics associated with a BRCA1 mutation were triple negativity (OR: 17.31), BBC history (OR: 4.96) and occurrence of OC (OR: 4.32). There were no major discerning components associated with BRCA2 mutations. Thus, we conclude that tumor pathology and FH of cancer might be considered together at the time of genetic testing mainly in countries where access to genetic testing is still restricted.

Indexed as

Genetic Predisposition to DiseaseMutationAdultBrazilBRCA1 ProteinBRCA2 ProteinBreast NeoplasmsFemaleFollow-Up StudiesGenetic TestingHumansIncidenceMiddle AgedOvarian NeoplasmsPrognosisBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanBRCA1 vs. BRCA2 mutated patientsfamily history of cancerhereditary breast cancer

Identifiers

PMID31244284
PMCPMC7021617
OpenAlexW2948627316

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.